FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer By Ogkologos - September 19, 2025 572 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During... October 19, 2020 Can Acupuncture Help Cancer Survivors with Chronic Pain? April 22, 2021 Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients... February 24, 2026 The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights... December 22, 2025 Load more HOT NEWS Helping Kids Cope With Cancer: “Your Stories” Podcast HTAN: Mapping Tumors across Space and Time Using Cutting-Edge Technologies Study presents an AI-guided approach to target cancer antigens Intensive Program Helps People Being Screened for Lung Cancer Quit Smoking
